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DOI: 10.1039/c0fo00132eFlavan-3-ols, occurring in monomeric, as well as in oligomeric and polymeric forms (also known as
condensed tannins or proanthocyanidins), are among the most abundant and bioactive dietary
polyphenols, but their in vivo health effects in humans may be limited because of their recognition as
xenobiotics. Bioavailability of flavan-3-ols is largely influenced by their degree of polymerization; while
monomers are readily absorbed in the small intestine, oligomers and polymers need to be
biotransformed by the colonic microbiota before absorption. Therefore, phenolic metabolites, rather
than the original high molecular weight compounds found in foods, may be responsible for the health
effects derived from flavan-3-ol consumption. Flavan-3-ol phenolic metabolites differ in structure,
amount and excretion site. Phase II or tissular metabolites derived from the small intestine and hepatic
metabolism are presented as conjugated derivatives (glucuronic acid or sulfate esters, methyl ether, or
their combined forms) of monomeric flavan-3-ols and are preferentially eliminated in the bile, whereas
microbial metabolites are rather simple conjugated lactones and phenolic acids that are largely excreted
in urine. Although the colon is seen as an important organ for the metabolism of flavan-3-ols, the
microbial catabolic pathways of these compounds are still under consideration, partly due to the lack of
identification of bacteria with such capacity. Studies performed with synthesized or isolated phase II
conjugated metabolites have revealed that they could have an effect beyond their antioxidant
properties, by interacting with signalling pathways implicated in important processes involved in the
development of diseases, among other bioactivities. However, the biological properties of microbe-
derived metabolites in their actual conjugated forms remain largely unknown. Currently, there is an
increasing interest in their effects on intestinal infections, inflammatory intestinal diseases and overall
gut health. The present review will give an insight into the metabolism andmicrobial biotransformation
of flavan-3-ols, including tentative catabolic pathways and aspects related to the identification of
bacteria with the ability to catabolize these kinds of polyphenols. Also, the in vitro bioactivities of phase
II and microbial phenolic metabolites will be covered in detail.I. Introduction
Proanthocyanidins or condensed tannins are polymers of flavan-
3-ols and are among the most abundant polyphenols in our diet.
Proanthocyanidins exhibit a wide range of biological activities,
including antioxidant, anti-carcinogenic, cardioprotective, anti-
microbial and neuro-protective activities, as has been demon-
strated in many in vitro and ex vivo studies.1 In the last decade,
a large body of epidemiological data has been accumulated
supporting the assumption that the consumption of flavan-3-ol-
rich food such as cocoa, red wine or tea may reduce the risk of
coronary heart disease (CHD).2–4 Proanthocyanidins exhibit
a high structural diversity and a wide range of degree of poly-
merization (DP), and their content varies considerably between
the different plant sources. Procyanidins, consisting of
(epi)catechin units, are the most abundant type of proantho-
cyanidins in nature. Propelargonidins and prodelphinidinsaInstitute of Industrial Fermentations (CSIC), Juan de la Cierva 3, 28006
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This journal is ª The Royal Society of Chemistry 2010contain (epi)afzelechin and (epi)gallocatechin units, respectively,
and are usually mixed with procyanidins. With regard to the
interflavanic bond nature, B-type procyanidins
[C-4 (upper unit)/C-6 or C-8 (lower unit)] are more abundant
than A-type procyanidins, which contain an additional ether-
type bond [C-2 (upper unit)–O–C-7 (lower unit)]. Fruits (grapes,
apples and pears), legumes, cocoa and beverages such as wine,
cider and beer are among the most important sources of B-type
proanthocyanidins.5 Polymeric proanthocyanidins with DP >10
represent the largest amount in 21 kinds of food.5 The daily
intake of flavan-3-ols in the United States has been estimated to
be around 60 mg/day for proanthocyanidins with a DP <2.5 In
the Spanish population it has been estimated to be 18–31 mg/day
when considering proanthocyanidins with a DP up to 3,6
and 450 mg/day when considering highly polymerized
proanthocyanidins.7
Polyphenols are recognized as xenobiotics (i.e. foreign or
artificial substances, usually of synthetic origin) by the human
organism, and therefore bioavailability is a factor that limits the
health benefits derived from proanthocyanidin consumption.
Bioavailability of proanthocyanidins is largely influenced by

































View Article Onlinethe small intestine, oligomeric and polymeric forms pass intact
through the gastrointestinal tract, reaching the colon where they
are transformed by the intestinal microbiota before absorption.
The scientific evidence accumulated during the last decade
indicates that the beneficial effect of these phytochemicals could
be attributed to the conjugated metabolites (formed during the
phase II metabolism of monomeric flavan-3-ols), and mainly to
metabolites derived from the microbial catabolism of proan-
thocyanidins, rather than to the original forms found in food
which have been widely used in most bioactivity studies.8–10
Recent studies have estimated that the amount of non-absorb-
able polyphenols reaching the colon is very high and that
microbe-derived phenolic metabolites excreted in urine represent
the largest proportion of polyphenol intake. This recognition is
leading to a reformulation of estimated bioavailability values
and the potential bioactivity of polyphenols.11 Currently, there is
an increasing interest in the determination of the possible health
implications derived from the interaction between phenolic
compounds and human microbiota, in particular concerning the
effect on microbiota composition and gut health. However, the
biological properties of microbial-derived metabolites are still
largely unknown.
The aim of the present review is to provide updated informa-
tion on metabolites formed from dietary flavan-3-ols, as well as
their bioactivity and potential health effects. After giving
a general overview about the bioavailability of dietary flavan-3-
ols in humans, structures of main phase II or tissular metabolites
derived from small intestine and liver metabolism are presented.Fig. 1 Schematic diagram of organs, reactions and ag
234 | Food Funct., 2010, 1, 233–253A special section is dedicated to the microbial catabolism of
monomeric flavan-3-ols and proanthocyanidins, describing
possible catabolic pathways, microbial reactions, and charac-
teristic metabolites derived from the biotransformation process.
Intrisic characteristics of candidate catabolic bacteria and
structural flavan-3-ol features limiting bacteria degradation are
also discussed. Finally, the main biological activities reported for
both phase II or tissular and microbial metabolites derived from
flavan-3-ols are reviewed, taking into consideration the results of
studies performed with conjugated metabolites at in vivo
concentrations.II. Bioavailability of monomeric flavan-3-ols and
proanthocyanidins
Bioavailability is a key issue linking polyphenols and health
effects. In the case of flavan-3-ols, the degree of polymerization
(DP) and galloylation are factors affecting their bioavailability
(Fig. 1). Monomeric flavan-3-ols are absorbed in the small
intestine and extensively metabolized into glucuronide conju-
gates by phase II enzymes.12,13 These metabolites can reach the
systemic circulation or be eliminated in the bile. Further
metabolism into sulfate conjugates and methyl derivatives occurs
in the liver. However, oligomers with DP >3 and polymers are
not absorbed in the small intestine and reach the colon, where
they are subjected to microbial catabolism. Microbial
metabolites are further absorbed and metabolized by phase II
enzymes, to finally enter the circulation or be eliminated in urine.ents involved in the bioavailability of flavan-3-ols.

































View Article OnlineII.1 Absorption and metabolism of monomeric flavan-3-ols
With regard to small intestine and liver metabolism, the small
intestine is the main site for glucuronidation, which occurs in the
luminal part of the endoplasmic reticulum via the superfamily of
uridine 50-diphosphate glucuronosyltransferases (UGTs). In
particular, UGT1 is considered to be responsible for the
glucuronidation of flavonoids.14 Sulfation and methylation
mainly occur in the liver through cytosol sulfotransferases
(SULT) and catechol-O-methyltransferase (COMT). Specifi-
cally, SULTA1 and SULTA3 are considered to be responsible
for the sulfation of ()-epicatechin.15 The preferred positions for
conjugation are the hydroxyl groups at C-30 and C-40 (B ring),
and C-5 and C-7 (A ring) (Fig. 2). Generally, conjugated
metabolites of ()-epicatechin are presented in the form of
monoglucuronides (5-, 7- and -30-O-glucuronides), sulfates
(7-O-sulfate), methyl ethers (30- and 40-O-methyl) or as combined
derivatives (30-O-methyl-7-O-glucuronide, 40-O-methyl 5- or -7-
O-glucuronide).16–19 In the case of ()-epigallocatechin (EGC),
the 30- and 7-O-glucuronides and the 40-O-methyl and its
derivatives (40-O-methyl-30-O-glucuronide, 40-O-methyl-7-O-
glucuronide, and 40-O-methyl-30-sulfate) have been identified
following consumption of green tea.20–24
In general, O-sulfated metabolites of ()-epicatechin are the
predominant metabolites in urine samples after the intake of
a single nutritional dose of cocoa powder in humans.25 However,
O-methyl-O-sulfate derivatives of ()-epicatechin have been
found as major urinary metabolites, followed by glucuronide,
sulfate and methyl-glucuronide conjugates, after the intake by
humans of a single dose of flavonol-rich cocoa powder.26 MajorFig. 2 Chemical structure of conjugated metabolites of ()-epicatechin, (
This journal is ª The Royal Society of Chemistry 2010urinary amounts of (epi)catechin-O-methyl-O-sulfates, followed
by sulfates and glucuronide conjugates, have also been reported
after the intake of a single dose of tea extracts in humans.27–29
Among O-glucuronides, the 30-O-glucuronide is the main
glucuronide derivative of both ()-epicatechin and EGC in
humans.17,22,24,30 EGC-40-O-methyl is the major methylated
metabolite of EGC after tea intake in humans.23
Among the different pairs of diastereomers, ()-epicatechin
presents higher absorption than (+)-catechin,16 but the latter is
more bioavailable than ()-catechin.31With regard to galloylated
monomers, ()-epicatechin-3-O-gallate (ECG) seems to be better
absorbed than ()-epigallocatechin-3-O-gallate (EGCG),27–29,32
but is considerably less bioavailable than the non-galloylated
monomers. No conjugated metabolites of the 3-O-galloylated
flavan-3-ols (ECG and EGCG) have been detected in biological
fluids. The possible hydrolysis of ECG after absorption was
suggested at first, but no esterases have been described in plasma
or liver, being found only at the level of the oral cavity.33 It has
been suggested that the low Cmax of EGCG is probably due to
not all possible conjugated forms being identified, particularly
those conjugated in the gallic acid ring such as EGCG-40 0-O-
methyl, EGCG-40,40 0-di-O-methyl, and EGCG-400-O-glucuro-
nide24,34 (Fig. 2). Recently, a new 7-O-glucopyranosyl-EGCG-
40 0-O-glucopyranoside has also been identified.21 Other studies
have confirmed that both ECG and EGCG, but in particular the
latter, also appear in unmetabolized form in plasma.28,35–37
Conjugated forms of monomeric flavan-3-ols usually reach
a Tmax at 1.5 h after ingestion, which is characteristic of
absorption in the small intestine.38)-epigallocatechin (EGC) and ()-epigallocatechin-3-O-gallate (EGCG).

































View Article OnlineII.2 Absorption and metabolism of dimeric proanthocyanidins
In the last decade, the absorption and metabolism of dimeric
proanthocyanidins have been a subject of speculation. It was first
thought that procyanidins could be depolymerized into
bioavailable monomers under the acidic conditions of the
stomach,39 but later studies failed to demonstrate this occurrence
in vivo.40–42 In contrast to monomers, glucuronidated or sulfated
metabolites of dimeric procyanidins have not been detected in
biological fluids,43 although some methylated forms have been
reported.44 Procyanidins B1 [epicatechin-(4b/8)-catechin] and
B2 [epicatechin-(4b/8)-epicatechin] have been detected in their
intact form at very low levels in human plasma (nM range) after
consumption of cocoa45 or grape seeds,46 and present the lowest
Cmax in plasma among flavonoid compounds.
13 Besides dimer
B2, procyanidin B5 (epicatechin-(4b/6)-epicatechin) has also
been detected in the plasma of rats fed cocoa extracts,47,48 but it
was not detected in human plasma after cocoa consumption.45
However, dimer B3 [catechin-(4a/8)-catechin] and trimer C2
[catechin-(4a/8)-catechin-(4a/8)-catechin] were not detected
in the plasma of rats fed the corresponding purified
compounds.49 Recently, oligomers with DP 2–5 have beenFig. 3 Metabolic pathway tentatively proposed for the catabolism of monom
236 | Food Funct., 2010, 1, 233–253detected in rat plasma after the administration of apple
procyanidin fractions (1 g/kg weight) with the same DP.44III. Microbial catabolism of monomeric flavan-3-ols
and proanthocyanidins
It has been estimated that 90–95% of dietary polyphenols are not
absorbed in the small intestine and therefore accumulate in the
colon.50 In the case of flavan-3-ols, in studies performed with
ileostomy patients (i.e. patients whose colon has been removed
surgically), it was calculated that approximately 70% of the
ingested monomeric flavan-3-ols from green tea could pass from
the small to the large intestine, with 33% corresponding to the
intact parent compounds.29 Recently, it has been reported that
after oral administration of [14C]procyanidin B2, 63% of the total
radioactivity was excreted via urine, indicating that a large
quantity of the parent compound is degraded by the gut micro-
flora.51 The recognition that the colon is a very active organ for
the metabolism of flavan-3-ols, particularly proanthocyanidins,
has led to a resurgence in the study of the biotransformation of
these compounds and other polyphenols by the intestinaleric flavan-3-ols and dimeric procyanidins by the intestinal microbiota.

































View Article Onlinemicrobiota8,10 and their implication in the overall bioavailability
and bioactivity of polyphenols.III.1 First steps of the catabolism of flavan-3-ols: formation of
hydroxyphenylvalerolactones and valeric acids
The complex catabolism of B-type proanthocyanidins involves
C-ring opening, followed by lactonization, decarboxylation,
dehydroxylation, and oxidation reactions, among others.10
Although numerous in vitro fermentation and in vivo studies have
been carried out in recent years, the accumulated knowledge has
only led to partial elucidation of the catabolic route of mono-
meric and B-type dimeric structures49,52–55 (Fig. 3). In the case of
galloylated monomeric flavan-3-ols (ECG and EGCG), the
microbial catabolism usually starts with the rapid cleavage of the
gallic acid ester moiety by microbial esterases, giving rise to gallic
acid which is further decarboxylated into pyrogallol.56–58 The
C-ring is subsequently opened, giving rise to diphenylpropan-2-
ol, which is later converted into 5-(30,40-dihydroxyphenyl)-g-
valerolactone (in the case of (epi)catechins) or
5-(30,40,50-trihydroxyphenyl)-g-valerolactone (in the case of
(epi)gallocatechins).56,58,59 The valerolactone ring later breaks,
giving rise to 5-(30,40-dihydroxyphenyl)valeric acid and/or
4-hydroxy-5-(30,40-dihydroxyphenyl)valeric acid. The identifica-
tion of this latter compound was firstly proposed by Khori et al.57
and recently confirmed by Llorach et al.60 in urine samples
collected after cocoa consumption in humans, as well as by
Stoupi et al.61 after in vitro fermentations carried out with human
faeces in the presence of ()-epicatechin and procyanidin B2.
Although it was first proposed that 4-hydroxy-5-(hydroxy-
phenyl)valeric acids could arise from the degradation of diphe-
nylpropan-2-ols, concurrently with hydroxyphenyl-g-
valerolactones57 (Fig. 3), it has recently been suggested that they
are formed instead from hydroxyphenyl-g-valerolactones, and
that an interconversion between both forms [4-hydroxy-5-
(hydroxyphenyl)valeric acids and 5-(hydroxyphenyl)-g-valer-
olactones] may exist, but is largely displaced towards the
formation of the formers.61 Subsequent biotransformations of
these valeric acids give rise to hydroxyphenylpropionic and
hydroxybenzoic acids by successive loss of carbon atoms from
the side chain through b-oxidation.56III.2 Metabolites arising from the catabolism of dimeric
procyanidins
The possible formation of 3,4-dihydroxyphenylacetic acid via a-
oxidation of 3,4-dihydroxyphenylpropionic acid (as described
for tyrosine49,62) in the microbial catabolism pathway of mono-
meric flavan-3-ols, has been widely debated. Firstly, it was
thought that 3,4-dihydroxyphenylacetic acid was only charac-
teristic of the catabolism of dimeric procyanidins;63 however,
other authors have recently proposed a-oxidation as a possible
pathway for the formation of this compound in the case of both
monomers and dimers,61 without discarding other possible
pathways, as proposed by Appeldoorn et al.54 in the case of
dimers. According to these latter authors, 3,4-dihydroxy-
phenylacetic acid results from the cleavage of the upper unit of
dimeric procyanidins, whereas the lower unit gives rise to 5-(30,40-
dihydroxyphenyl)-g-valerolactone and to the triggering of theThis journal is ª The Royal Society of Chemistry 2010rest of the previously described route (Fig. 3). The possible
depolymerization of dimeric structures into monomeric units,
firstly proposed by Groenewoud et al.,64 has been recently
confirmed to occur but to a lesser extent,54,61 representing less
than 10% in the case of procyanidin B2.61 Other microbial
metabolites arising exclusively from the catabolism of dimeric
procyanidins have recently been identified, such as 5-(20,40-
dihydroxyphenyl)-2-ene-valeric acid, as well as other compounds
which have been tentatively identified as derivatives from the
A-ring of the upper unit, including the interflavanic bond.61III.3 Last steps of the catabolism of flavan-3-ols
Finally, the last steps of the microbial catabolism of (epi)catechin
involve dehydroxylation of 3,4-dihydroxylated phenolic acids at
C-40 (preferentially), and C-30, resulting in 3- and 4-mono-
hydroxylated phenolic acids, respectively.53,61 In the case of
(epi)gallocatechins, dehydroxylation preferentially occurs at C-5,
resulting in 3,4-dihydroxylated phenolic acids which undergo
further dehydroxylation at C-4 and C-3, as mentioned above.
However, in the case of hydroxyphenylvalerolactones, the
3,5-dihydroxylated derivative arising from the dehydroxylation
of 5-(30,40,50-trihydroxyphenyl)-g-valerolactone has also been
identified, indicating that dehydroxylation at C-40 occurs.20 Once
absorbed, the microbial metabolites from flavan-3-ols are mainly
metabolized in the liver by phase II enzymes as conjugated
derivatives that are subsequently eliminated in urine. At the same
time, a portion of microbial metabolites (non-conjugated
microbial metabolites) is eliminated in the faeces.
Several microbe-derived metabolites that have been detected in
urine in their actual conjugated form by targeted analysis
including: monoglucuronide and monosulfate of 5-(30,40- and
30,50-dihydroxyphenyl)-g-valerolactone, in addition to the
methyl-sulfate derivatives of 5-(30,40,50-trihydroxyphenyl)-g-
valerolactone.20,22,30,65 In the case of phenolic acids,
monoglucuronide and monosulfate conjugates of mono- and
di-hydroxyphenylpropionic and p-coumaric acids have been
reported.66 Other reactions occurring in the liver and kidney
include: glycine conjugation, dehydrogenation, hydroxylation
and methylation.53 The excretion of microbial metabolites varies
markedly between subjects, and for some individuals it may also
vary with the substrate, reaching a very high proportion (up to
50%) of the intake of polyphenols.8III.4 Main microbial phenolic metabolites found in urine
Several feeding studies have revealed significant changes in the
urinary excretion of microbe-derived phenolic acids after the
intake of rich sources of flavan-3-ols. Among phenolic acids,
mono- and di-hydroxylated phenylpropionic and phenylacetic
acids, together with hydroxyhippuric acids, have been found as
main urinary microbial phenolic acids derived from flavan-3-ol
intake.
With regard to cocoa and cocoa-derived products, Gonthier
et al.49 reported an increase in 3,4-dihydroxyphenylacetic and
3-hydroxyphenylacetic acids in urine after the administration of
procyanidin B3 to rats. Similarly, Rios et al.67 reported a signifi-
cant increase in the urinary excretion of these compounds, as well

































View Article Onlinehealthy humans after acute consumption of flavanol-rich choc-
olate. Recently, Urpi-Sarda et al.68 also found increased urinary
levels of 3,4-dihydroxyphenylacetic and 3-hydroxyphenylacetic
acids in humans after chronic consumption of cocoa powder with
milk. Other studies have reported an increased urinary excretion
of 3-hydroxypropionic and 3-hydroxyphenylacetic acids after
human consumption of grape seed polyphenols.69 In the case of
green tea, 3-hydroxyphenylpropionic and 4-hydroxyphenylacetic
and 4-hydroxyphenylacetic acids significantly increased in
human urine.58 Finally, 3-hydroxyphenylpropionic and
3-hydroxybenzoic acids were also reported to increase in the
urine of rats fed wine polyphenols.53
Besides these phenolic acids, which are also common to the
microbial catabolism of other flavonoids,10 5-(30,40,50-trihydroxy-
phenyl)-g-valerolactone and 5-(30,40-dihydroxyphenyl)-g-valer-
olactone are considered important microbial metabolites and
potential biomarkers of flavan-3-ol consumption in humans, as
has been confirmed after the intake of green tea,20,22,23,58 cocoa
products30 and almond skins.65,70IV. Intestinal bacteria with ability to catabolize
flavan-3-ols
It is important to mention that the above difference of opinions
concerning the possible catabolic route of monomeric and
dimeric flavan-3-ols could be partly attributed to differences in
the microbiota composition of faecal samples used in the
different studies, suggesting that different pathways could coexist
or one predominate over the others, depending on the catabolic
capacity of the microbiota. An important limitation in this area is
that bacteria belonging to humanmicrobiota with the capacity to
catabolize flavan-3-ols have still not been identified. To date,
only bacteria with the capacity to catabolize other types of
flavonoid compounds, mainly flavonols and flavones, have been
described. These bacteria, in general, belong to the Clostridium
and Eubacterium groups.10
Among the factors that may limit the identification of flavan-
3-ol catabolic bacteria, it is important to highlight the well-
known growth inhibitory effects of proanthocyanidins. Another
factor that deserves consideration is the structural features of
flavan-3-ols as complex non-planar molecules.IV.1 Inhibitory effects of proanthocyanidins and ‘‘tannin-
resistant’’ bacteria
The growth-inhibitory effects of proanthocyanidins on bacteria
have been reviewed by Smith et al.71 Tannins are capable of
complexing with polymers and minerals, making nutrients
unavailable. In addition, they could have a direct effect by
interacting with membranes, cell walls, and/or extracellular
proteins. ‘‘Tannin-resistant’’ bacteria have been defined as those
bacteria that are able to withstand the inhibitory effect of
tannins. ‘‘Resistance’’ implies that some action is required on the
part of the organism to withstand the inhibitory effect of tannins,
including inducible adaptation or even gene transfer.71 Tannin-
resistance may also depend on the tannin concentration, struc-
tural composition and DP. It is important to highlight the fact
that bacteria which are predominant in tannin-rich mediums may238 | Food Funct., 2010, 1, 233–253not be resistant per se, but are less affected by nutrient limitations
or are better able to access limiting nutrients.
‘‘Tannin-resistant’’ Gram-negative species (Enter-
obacteriaceae and Bacteriodes) have been isolated from rat faecal
samples after prolonged administration of condensed tannins
from Acacia angustissima, a forage legume.72 ‘‘Tannin-resistant’’
Gram-positive bacteria have also been identified. Brooker et al.73
isolated a Streptococcus strain (named S. caprinus and close to
S. bovis) from the rumen of goats which was able to grow at 2.5%
of condensed tannins. A Streptococcus strain (close to S. bovis
and S. gallolyticus) has also been isolated from the rumen of
sheep, goats and deer.74 Later, Molina et al.75 has also isolated
a Eubacterium strain (close to E. cellulosolvens) from the rumen
of moose, able to tolerate 0.5 g/L of condensed tannins.
Some mechanisms by which bacteria can overcome inhibition
by tannins include: modification/degradation of the substrate,
dissociation of tannin–substrate complexes, cell membrane
modification/repair and metal ion sequestration. It has been
reported that Bifidobacterium infantis and Lactobacillus acid-
ophilus are not inhibited by tannins because lactic acid bacteria
do not require iron as they do not depend on metal-chelating
enzymes, in particular heme enzymes.76 Moreover, in vivo studies
have revealed that consumption of grape seed extract, containing
40% of condensed tannins, produced an increase in the bifido-
bacteria population in healthy individuals.77 Although tannin
resistance is the first step in order for bacteria to metabolize
condensed tannins, resistance does not guarantee metabolic
activity, and the biodegradation pathway of ‘‘tannin-resistant’’
bacteria has not yet been described.IV.2 Structural features of flavan-3-ols limiting bacterial
catabolism
There is some evidence that the structural characteristics and
stereochemistry of flavan-3-ols could be limiting factors for
intestinal bacteria to be able to degrade these types of
compounds. It has been reported that Eubacterium ramulus was
unable to degrade (+)-catechin because of the absence of
a functional group at C-4 in this flavonoid structure.78 Similarly,
the human bacterium Eubacterium sp. (SDG-2) was able to open
the ring of the 3R [()-catechin and ()-epicatechin] and the 3S
[(+)-catechin and (+)-epicatechin] forms of monomeric flavan-3-
ols into 1,3-diphenylpropan-2-ols (Fig. 3), but was incapable of
producing the same fission in their galloylated esters.79 However,
in no instance was this bacteria able to continue the catabolism
up to the formation of 5-(30,40-dihydroxyphenyl)-g-valer-
olactone. Another characteristic of this bacterium was the ability
to dehydroxylate the OH groups in the B ring of 1,3-diphenyl-
propan-2-ols, but only of the R forms.79 This fact, together with
the inability to catabolize the gallate esters, suggests that the
spatial configuration of both the original flavan-3-ol molecule
and intermediate metabolites may limit the microbial degrada-
tion of flavan-3-ols. In fact, in a recent in vitro fermentation study
with human faeces it was found that (+)-catechin (2R,3S) was
firstly converted into (+)-epicatechin (2S,3S) by intestinal
microbiota in order for the biotransformation process to
proceed.80
Taken together, these findings suggest that it may be

































View Article Onlinewhole catabolic pathway proposed in Fig. 3, but rather the
catabolism may be carried out by different bacteria with
specific catabolic activities that work in sequential form on the
appearance of the different intermediate metabolites. Among
the different phases of the catabolic pathway, formation of
5-(30,40-dihydroxyphenyl)-g-valerolactone seems to be
a limiting step.V. Bioactivity of flavan-3-ol metabolites
As a consequence of their extensive metabolism in the human
organism, the original flavan-3-ol structures present in food are
not present in plasma and urine (with the exception of small
amounts of gallate ester of monomeric flavan-3-ols and dimeric
procyanidins that appear unmetabolized, as mentioned above)
but rather appear as a complex series of phase II or tissular
metabolites and, particularly, of microbe-derived phenolic
metabolites. Therefore, both types of circulating metabolites
should be responsible for the health benefits associated with the
consumption of dietary sources rich in flavan-3-ols.V.1 Bioactivity of phase II or tissular metabolites derived from
small-intestine and liver metabolism
One of the limitations of many in vitro and ex vivo studies which
have tried to unravel the health effects of flavan-3-ols has been
the use of unconjugated structures, as well as the use of test
concentrations (mM) at a much higher range than that found in
biological fluids (mM range). Taking this into consideration, this
section will only try to cover the results of studies performed with
conjugated metabolites in the micromolar or submillimolar
range (0.5–30 mM) found in plasma (Table 1).
In general, the conjugation process (glucuronidation, sulfation
and methylation) affects the physico-chemical properties of fla-
van-3-ols and, in turn, their residence in plasma, their excretion
rate, and finally the bioactive properties of the parent
compound.13 In particular, sulfation and glucuronidation
involve a considerable attenuation of biological activity. The case
of methylation seems to be more complex because the incorpo-
ration of methyl groups reduces the number of available OH
groups, but at the same time increases the lipophilic nature of the
compound, which can be advantageous for cellular uptake by
passive diffusion.13
Antioxidant activity. The antioxidant activity of flavonoid
metabolites has been widely studied, considering the fact that
oxidative stress is implicated in the initiation and progression
of chronic diseases. In the case of flavonoid compounds (i.e.
quercetin), it has been observed that glucuronidation at C-30
and C-40 of the B ring (catechol-type structure) produces
a greater loss of antioxidant capacity than when it occurs at C-
3 of the C ring.81–83 In contrast, glucuronidation at C-7 (A ring)
seems to produce a slight increase in antioxidant activity.83 In
the case of flavan-3-ol metabolites, ()-epicatechin and its 7-O-
glucuronide presented a similar delay of Cu2+-induced LDL
oxidation, whereas the activities of the 30-O-glucuronide and
the 40-O-methyl-30-O-glucuronide were significantly lower.84
However, in the case of galloylated (epi)gallocatechins, the
position of glucuronidation affected the anti-radical capacityThis journal is ª The Royal Society of Chemistry 2010against DPPH differently to the other flavonoids, since EGCG-
7-O-glucuronide and EGCG-40 0-O-glucuronide (galloylation in
the gallic acid ring) were less active than the aglycone, whereas
the 30- and 300-O-glucuronides showed the same activity as the
aglycone.24 For non-galloylated (epi)gallocatechins, EGC-7-O-
glucuronide and -30-O-glucuronide were more active than the
aglycone.24
In the case of O-methylation, Cren-Olive et al.85 also reported
that the catechol B-ring was also the active moiety of (+)-cate-
chin, since the 30- and 40-O-methyl ethers and 30,40-di-O-methyl
ether showed a much lower inhibition of Cu2+-induced LDL
oxidation than the aglycone, but the activity was recovered when
these positions were free, as in the 5,7-di-O-methyl analogue. The
C-30 and C-40-O-methyl ethers of ()-epicatechin also showed
a lower inhibition of peroxynitrite-induced tyrosine nitration
than the parent compound.86 Similarly, O-methylation at posi-
tion C-30 in ()-epicatechin, ()-epigallocatechin and ()-epi-
catechin-3-O-gallate elicited a potential inhibition of lipid
oxidation of canola oil in comparison to the aglycone.87 In
a recent study, C-30 and C-40-O-methyl ethers of (+)-catechin and
()-epicatechin showed a lower antioxidant capacity than the
parent compound, as measured by the ferric-reducing power
(FRAP) and by the ability to scavenge the ABTS+ radical
cation.88 Moreover, the antioxidant activity of these metabolites
was found to be pH dependent, but significant radical scavenging
activity was found to be retained at pH 7.4, suggesting that they
could act as potential antioxidants under physiological
conditions.88
Vascular effects. Epicatechin and its metabolite, epicatechin-7-
O-glucuronide, have been identified as independent predictors of
the vascular effects observed after flavanol-rich cocoa intake.19
Anti-inflammatory effects. In the case of EGCG metabolites,
glucuronidation at C-7 affected the ability to inhibit the
production of NO or the arachidonic acid metabolism in HT29
cells compared to the aglycone, but it was not affected in the case
of glucuronidation at C-30, C-300, C-40 0.24 Conversely, in the case
of ECG, glucuronidation at C-30 decreased such capacity by 20%
compared to the aglycone, but it was not affected in the case of
the 7-O-glucuronide.24
Inhibition of cellular growth. The effectiveness of ()-epi-
catechin metabolites on the inhibition of cellular growth has been
studied in various types of cell lines. In the case of neuronal cells,
it has been reported that 30-O-methyl-epicatechin was as effective
as ()-epicatechin in the inhibition of apoptosis induced by
oxidized LDL.89 Similarly, it has been reported that 30-O-methyl-
epicatechin was as efficient as ()-epicatechin in protecting
human fibroblasts against cell death induced by oxidative
stress.90 In the case of galloylated flavan-3-ol metabolites,
methylation at C-40 and C-40 0 in ()-epigallocatechin-3-O-gallate
(EGCG) produced a 50% decrease in the growth-inhibitory and
pro-apoptotic activities of murine osteoclasts, compared to
EGCG.91 In another study, methylated derivatives of EGCG at
positions C-40 0 and C-40-40 0 (dimethyl derivative) presented less
inhibitory capacity than EGCG of the enzyme 20S proteasome,
which catalyzes the degradation of intracellular proteins and is


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































View Article OnlineInteraction with cellular signalling pathways. In recent years, it
has been suggested that polyphenols may exert their health
effects via a mechanism of action beyond their antioxidant
activity, and which is more related to its ability to generate an
adaptive response at the cellular level that involves interaction
with certain key proteins in triggering cell signalling pathways of
oxidative stress and exposure to environmental toxins.9 In the
case of flavan-3-ols, most studies have been performed mainly
with the non-conjugated forms. It has been reported that EGCG
induces apoptosis and causes cell-cycle arrest in tumor cells – but
not in non-transformed normal cells – through the modulation of
nuclear factor kappa-B (NF-kB). NF-kB is a redox-sensitive
transcription factor which regulates the expression of pro-
inflammatory cytokines, iNOS, COX-2, growth factors and
inhibitors of apoptosis, and is related to inflammatory diseases
(atherosclerosis, ulcerative colitis and rheumatoid arthritis), as
well as neurodegenerative diseases and cancer.93,94 In another
study, EGCG was also found to down-regulate NF-kB-inducing
kinase (NIK), death-associated protein kinase (DPAK 1), and
rho B and tyrosine protein kinase in PC-9 human lung cancer
cells.95 A down-regulation of genes involved in a wide range of
physiological functions was found in the mucosa of rats with
induced colon carcinogenesis that had been fed wine polyphenols
for 16 weeks, being the major pathways down-regulated those
involved in the inflammatory response and steroid metabolism.96
With regards to genes involved in relevant process of athero-
sclerosis, red wine polyphenols were also found to significantly
inhibit the proliferation of human vascular smooth muscle cells –
but not of human vascular endothelial cells – by reducing the
promoter activity and expression of the cyclin A gene.97 Green
tea polyphenols have been shown to modulate the regulation of
the transcriptional expression of proatherogenic molecules,
including the sterol-response element binding protein (SREBP),
PPAR-g, IL-8, and apoprotein-E.98V.2 Bioactivity of microbe-derived phenolic metabolites
The biological activities of microbial metabolites derived from
the catabolism of flavan-3-ols are still largely unknown, but in
recent years those of hydroxyphenyl-g-valerolactones, and
especially of phenolic acids (di- and mono- hydroxylated phe-
nylproponic, phenylacetic, benzoic acids and derivatives) formed
from the subsequent catabolism of the former, have started to be
unravelled. In contrast to phase II or tissular metabolites derived
from small-intestine and liver metabolism as described above, to
date, in vitro studies performed with microbe-derived phenolic
metabolites have been carried out with unconjugated metabolites
(with the exception of hippuric acids) (Table 2).
V.2.1 Hydroxyphenyl-g-valerolactones
Antioxidant activity. The antioxidant activity of 5-(30,40-
dihydroxyphenyl)-g-valerolactone and its methyl derivative
5-(30-methoxy-40-hydroxyphenyl)-g-valerolactone has been
tested against superoxide radicals, as well as by the ferric-
reducing antioxidant potential (FRAP) test.99 In the radical
scavenging test, 5-(30,40-dihydroxyphenyl)-g-valerolactone was
more effective than (+)-catechin, ascorbic acid and trolox,
whereas 5-(30-methoxy-40-hydroxyphenyl)-g-valerolactone did

































View Article Onlinevalues was: 5-(3,4-dihydroxyphenyl)-g-valerolactone >
(+)-catechin > ascorbic acid > 5-(3-methoxy-4-hydroxyphenyl)-
g-valerolactone.99
Anti-proliferative activity. 5-(30,40,50-Trihydroxyphenyl)-g-
valerolactone was more effective in the inhibition of the growth
of a series of immortalized and malignant human cell lines than
its trimethoxylated derivative, with the exception of HCT-116
colon cancer cells, and immobilized human (INT407) and
rat (IEC-6) intestinal cells, which were not sensitive to the
growth-inhibitory effects of this compound.100 5-(30,40,50-Trihy-
droxyphenyl)-g-valerolactone was also more effective in the
inhibition of the growth of colon (HT-29) and oesophagus
(KYSE150) cancer cells than 5-(30,40-dihydroxyphenyl)-g-valer-
olactone and its mono- and di-methoxylated derivatives.100
However, the growth-inhibitory effects of this metabolite were
lower than that of the aglycone, EGCG. Treatment of KYSE150
with 5-(30,40,50-trihydroxyphenyl)-g-valerolactone at 50 mM
resulted in a 40% cell-growth inhibition after 48 h, whereas
EGCG resulted in a 50% inhibition at 20 mM.100
Anti-inflammatory effects. The inhibition of NO production in
murine macrophage cells (RAW264.7) by 5-(30,40,50-trihydrox-
yphenyl)-g-valerolactone and its trimethoxylated derivative has
also been described.100 Whereas the former metabolite had
IC50 ¼ 20 mM, the latter metabolite did not present any activity.
However, none of the metabolites had inhibitory activity
towards arachidonic acid metabolism in the same cell model.100
On the other hand, 5-(30,40-dihydroxyphenyl)-g-valerolactone
and its methyl derivative 5-(30-methoxy-40-hydroxyphenyl)-g-
valerolactone had similar inhibitory activity of the enzymatic
activity of matrix metalloproteinases (MMP-1, MMP-2 and
MMP-9).99 Both metabolites also had similar efficacy in the
inhibition of the secretion of MMP-9 from LPS-stimulated
human monocytes.99
V.2.2 Phenolic acids
Effects on intestinal microbiota. Some phenolic acids,
including 3-O-methyl gallic, gallic, caffeic, 4-hydroxy-
phenylpropionic, phenylpropionic, and 4-hydroxyphenylacetic
acids derived from the microbial degradation of tea catechins,
were able to inhibit the growth of several pathogenic and non-
beneficial intestinal bacteria without significantly affecting
the growth of beneficial bacteria (Lactobacillus spp. and
Bifidobacterium spp.).101 Other studies have revealed that dihy-
droxylated forms (i.e. 3,4-dihydroxyphenylacetic and 3,4-dihy-
droxyphenylpropionic acids) efficiently destabilize the outer
membrane of Salmonella.102 Recently, Cueva et al.103 found that
the number and position of substitutions in the benzene ring of
phenolic acids and the saturated side chain length influenced the
antimicrobial potential of phenolic acids against different micro-
organisms (Escherichia coli, Lactobacillus spp., Staphylococcus
aureus, Pseudomonas aeruginosa and Candida albicans), although
it was strain-dependent. In general, non-hydroxylated and
monohydroxylated phenolic acids were more potent than dihy-
droxylated or disubstituted phenolic acids. With regard to the
saturated side chain, the order of potency, for the same benzene
ring-substitution, was benzoic > phenylacetic > phenylpropionic
acid. Moreover, Lactobacillus spp. and S. aureus (Gram-positive)This journal is ª The Royal Society of Chemistry 2010appeared more susceptible to the action of a series of microbial
phenolic acids than Gram-negative bacteria, such as E. coli and
P. aeruginosa.103
Antioxidant activity. Among a series of microbe-derived
phenolic acids, 3,4-dihydroxyphenylacetic and 3,4-dihydroxy-
toluene exhibited the highest radical scavenging activity against
DPPH in cultured rat hepatocytes.104 However, only the latter
metabolite was found to be effective against the lipid perox-
idation of rat hepatocytes challenged with tert-butyl-hydroper-
oxide.104
Anti-thrombotic activity. Rechner et al.105 studied the effect of
several microbe-derived phenolic acids and their mixture on
platelet function through several tests, including: platelet aggre-
gation, P-selectin expression on resting platelets, effect on
TRAP-induced platelet activation and epinephrine-stressed
platelets. Dihydrocaffeic acid (3,4-dihydroxyphenylpropionic
acid), dihydroferulic acid (4-hydroxy-3-methoxy-
phenylpropionic acid) and 3-hydroxyphenylpropionic acid, as
well as the polyphenol mixture, were among the metabolites with
the best activity in all tests performed.105
Anti-inflammatory activity. Studies carried out by Karlsson
et al.106 showed that faecal samples containing microbial
phenolic acids affected cyclooxygenase-2 (COX-2) protein levels
in colon cancer cells (HT-29) stimulated with TNF-a. Recently,
Russell et al.107 reported that phenolic acids presenting
4-hydroxy-3-methoxy substitution and a one-carbon side chain
such as vanillic acid and its derivatives (vanillin, vanillyl alcohol
and acetovanillone), as well as a three-carbon side chain (cin-
namic, o-, m- and p-coumaric acid, and caffeic acid), inhibited
cytokine-induced prostanoid biogenesis in human colonic
fibroblasts. A structure–activity relationship has been observed
between phenolic acids and their anti-inflammatory effects, since
only dihydroxylated phenolic acids (i.e. 3,4-dihydrox-
yphenylpropionic and 3,4-dihydroxyphenylacetic acids) signifi-
cantly inhibited the production of pro-inflammatory cytokines
TNF-a, IL-1b, IL-6 in peripheral blood mononuclear cells
(PBMC) stimulated with LPS, whereas no significant effect was
found for the monohydroxylated ones.108 Similarly, Larrosa
et al.109 recently found that these dihydroxylated phenolic acids
provided the best inhibition of prostaglandin E2 production in
cancer cells of fibroblast (CCD-18) stimulated with IL-1b. In vivo
experiments with rats have also shown that 3,4-dihydrox-
ypropionic acid was the most potent metabolite in writhing and
paw pressure tests in rodents and reduced the expression of
cytokines TNF-a, IL-1b, IL-8, as well as the levels of malo-
naldehyde and oxidative damage to DNA in the distal mucosa of
rats with dextran sodium sulfate (DSS)-induced colitis.109
Anti-proliferative activity and cytotoxicity. Among a series of
microbial phenolic metabolites, 3,4-dihydroxyphenylacetic acid
presented anti-proliferative activity in prostate (LNCaP) and, in
particular, in colon cancer (HCT116) cells.110 In vivo studies have
also revealed that protocatechuic acid reduces the incidence and
multiplicity of cancerous tumors in the colon of rats.111 The
modulation of cytochrome P450 and enzymes involved in

































View Article Onlineenzymes) by protocatechuic acid in mouse liver and kidney has
also been reported.112Moreover, protocatechuic acid affected the
level of rat hepatic and renal glutathione S-transferase (GST)
isoenzymes.113 Cytotoxicity assays have also shown that proto-
catechuic acid effectively kill the HepG2 hepatocellular carci-
noma cells by stimulating the c-Jun N-terminal kinase (JNK) and
p38 subgroups of the mitogen-activated protein kinase (MAPK)
family.114 A similar signalling pathway has been reported to be
involved in the apoptosis of human gastric adenocarcinoma cells
by protocatechuic acid.115 In a recent study, protocatechuic acid
has also shown significant neuroprotective effects on retenone-
induced apoptosis in PC12 cells by ameliorating the mitochon-
drial dysfunction.116
Modulation of lipid metabolism. It has been reported that 3,4-
dihydroxytoluene acid inhibits the synthesis of heptocellular
cholesterol by inhibiting the incorporation of acetate into HepG2
liver cells.104VI. Concluding remarks
Over the last decade, a large number of epidemiological and
interventional studies have demonstrated that there may be an
association between flavonoid consumption and human health.
Mechanistic studies trying to determine flavan-3-ol health effects
have revealed that these polyphenols exhibit a wide range of
biological effects. Despite the enormous effort devoted to this
area, some results may be misleading, since polyphenol metab-
olism as xenobiotics has not been considered in a large number of
studies which employed structural forms and concentration
ranges not found in vivo. Therefore, polyphenol bioavailability is
a key issue in the link between polyphenol and human health. In
comparison to other micronutrients, knowledge about poly-
phenol bioavailability is advancing with the progress of analyt-
ical instrumentation which allows the identification of new
metabolites in vivo. The recognition that some polyphenols, in
particular proanthocyanidins, are extensively metabolized by the
intestinal microbiota into low molecular weight compounds, and
that these metabolites represent a very large percentage of the
amount ingested, is bringing into consideration the inclusion of
microbial metabolism as part of the bioavailability concept
currently adopted for polyphenols. On the basis of these
facts, interest is now focused on the study of the bioactivity of
microbe-derived metabolites, in addition to phase II or tissular
metabolites, as compounds responsible for the health effects of
flavan-3-ols. Although advances are being made in the determi-
nation of the bioactivity of microbe-derived metabolites, most
studies carried out until now have failed, again by not testing the
conjugated forms found in vivo. With regards to the bioactivity of
actual conjugated forms derived from flavan-3-ol in vivo
metabolism, research carried out in the last decade has revealed
that flavan-3-ols are multifunctional compounds that may
display effects by mechanism(s) of action beyond their antioxi-
dant activity.
The health effects derived from the interaction between flavan-
3-ols and the intestinal microbiota should be a subject of
increasing interest. Although some authors have pointed out that
polyphenols may be beneficial to gut health by increasing the
population of potentially beneficial bacteria or exerting prebiotic250 | Food Funct., 2010, 1, 233–253actions, the effects that the interaction between flavan-3-ols and
intestinal microbiota may have on the functionality of the
metabolic activity of the microbiota and overall gastrointestinal
health still remains largely unknown. In fact, for flavan-3-ols to
function as a prebiotic, intestinal bacteria with such metabolic
capacity should exist in the colon, but they are difficult to identify
due to direct or indirect factors inherent in flavan-3-ols. The
identification of flavan-3-ol-metabolizing bacteria and their
possible use as a probiotic could be a good strategy for increasing
the bioavailability and potential bioactivity of
proanthocyanidins.Acknowledgements
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